Mycophenolate Mofetil Shortage Update: What Patients Need to Know in 2026

If you take mycophenolate mofetil for a kidney, heart, or liver transplant — or for an autoimmune condition like lupus or vasculitis — you may have noticed your pharmacy struggling to keep it in stock. Supply disruptions affecting multiple manufacturers have made this critical immunosuppressant harder to obtain at certain times and locations across the United States.

This article provides the most current patient-focused update on the mycophenolate mofetil shortage in 2026 — what's happening, which formulations are most affected, and the concrete steps you can take right now.

What Is the Current Shortage Status for Mycophenolate Mofetil?

Mycophenolate mofetil capsules and tablets remain on the ASHP (American Society of Health-System Pharmacists) drug shortage list, with multiple generic manufacturers reporting supply constraints. Affected manufacturers have included Mylan, Sandoz, Hikma, Accord, Ascend, and Teva — representing a significant portion of the total generic supply.

The shortage does not mean the medication is completely unavailable — rather, it is inconsistently available. Some pharmacies have stock while others in the same city or region do not. This creates a patchwork availability problem that requires active searching rather than waiting for a restock at your usual pharmacy.

Which Formulations Are Most Affected?

Not all mycophenolate products are equally impacted. Here's the breakdown as of 2026:

• Generic 250 mg capsules: Supply is inconsistent across manufacturers. Sandoz, Mylan, Hikma, Accord, and Ascend have all had allocation or back-order issues at various times.
• Generic 500 mg tablets: The most commonly prescribed form; similarly affected by multi-manufacturer constraints.
• Brand-name CellCept (Genentech): Generally more reliably available than generics. Patients prescribed brand-name CellCept may face fewer stock issues, though it is significantly more expensive without insurance coverage or a savings card.
• Mycophenolate sodium delayed-release tablets (Myfortic/generic): Generic versions (Apotex, Major) have had back-order issues; Mylan and brand-name Myfortic (Novartis) have maintained better availability.
• Myhibbin oral suspension: FDA-approved in May 2024 by Azurity Pharmaceuticals. A ready-to-use liquid formulation for patients who cannot swallow capsules or tablets. This newer formulation has not been subject to the same shortage pressures as older oral solids.

Why Is This Shortage Happening?

Several structural forces are driving the shortage:

• Manufacturing concentration. Generic drugs like mycophenolate mofetil have thin profit margins, leading to few manufacturers making the product. When any one facility faces disruptions, the whole supply chain is affected.
• Plant closures and quality issues. In 2023, the End Drug Shortages Alliance specifically identified mycophenolate mofetil as at high risk following a pharmaceutical plant closure, alongside other essential medications.
• Soaring demand. U.S. organ transplants topped 46,000 in 2023 — an all-time record. At the same time, off-label prescribing for autoimmune diseases has grown, with autoimmune indications now representing nearly 45% of all MMF prescriptions. More patients need the drug long-term.
• Supply chain unpredictability. ASHP data shows the cause of more than half of all active drug shortages in 2024 was officially listed as unknown — a reflection of the complexity and opacity of pharmaceutical supply chains.

How Serious Is the Shortage for Transplant Patients?

For transplant recipients, mycophenolate mofetil is not optional. It is a cornerstone of long-term immunosuppression that prevents the immune system from rejecting a transplanted organ. Missing even a few doses can increase the risk of acute rejection. If you are a transplant recipient and cannot fill your prescription, this is a medical urgency — contact your transplant center the same day.

What Patients Should Do Right Now

Here's a prioritized action checklist:

1. Don't wait until you're out. Start refilling 7-10 days before you run out. Most insurance plans allow refills when 75-80% of the supply is used.
2. Call multiple pharmacies. Chain pharmacies, independent pharmacies, and hospital outpatient pharmacies may have different inventory levels.
3. Use medfinder to search pharmacies near you without making dozens of calls yourself.
4. Ask your prescriber about alternatives. Brand-name CellCept, a different strength, or mycophenolate sodium (Myfortic) may be accessible options.
5. Consider mail-order. Your insurance plan's mail-order pharmacy may have 90-day supplies available when retail locations don't.
6. Contact your transplant center (if applicable). Transplant teams have experience navigating shortages and may have access to bridge supplies or solutions retail pharmacies don't.

What Are Experts Saying About the Overall Drug Shortage Problem?

ASHP data from 2025 shows active shortages in the United States numbered around 270 in Q1 2025 — down from an all-time high of 323 in early 2024, but still historically elevated. ASHP's senior director of pharmacy practice has noted that 'new shortages are occurring at about the same rate that older shortages are resolving,' and that the root cause is a challenging economic environment for generic drug production.

For patients on critical medications like mycophenolate mofetil, this means proactive planning is now a permanent part of managing your health — not just something to think about during acute shortages.

For more detailed guidance, see: How to Find Mycophenolate Mofetil in Stock Near You and Alternatives to Mycophenolate Mofetil If You Can't Fill Your Prescription.